Cathepsin L is a protein-cutting enzyme found inside nearly every cell in your body, tucked away in compartments called lysosomes where it breaks down and recycles other proteins. In healthy tissue it performs quiet housekeeping: helping the immune system, maintaining skin and hair, and clearing cellular debris. But when its activity goes haywire, cathepsin L becomes a factor in cancer spread, heart disease, neurodegeneration, and viral infections including COVID-19 and Ebola. That dual identity makes it one of the more intriguing drug targets in current biomedical research.
What Cathepsin L Actually Does in Healthy Cells
Cathepsin L belongs to a family of enzymes called cysteine cathepsins, named for the cysteine amino acid at their active site that does the cutting. It is produced as an inactive precursor called pro-cathepsin L, which only switches on under acidic conditions. Early biochemistry work showed that this activation happens readily at a pH around 5.5 in the presence of negatively charged surfaces, and that a small fraction of already-active enzyme is needed to kick-start the process, after which conversion to the mature form accelerates quickly.1Biochemical and Biophysical Research Communications. Surface activation of pro-cathepsin L This pH-dependent switch is important because it keeps cathepsin L safely inactive in the neutral pH of the rest of the cell while allowing it to work inside the acidic lysosome.
Once active, cathepsin L’s main job is protein turnover within the lysosome: chopping up old, damaged, or unneeded proteins so their building blocks can be reused. It also plays a specialized role in autophagy, the process cells use to package and digest their own worn-out components. While most lysosomal enzymes digest whatever arrives in the autophagosome, cathepsin L is more selective. It preferentially degrades specific membrane markers on the autophagosome itself, rather than bulk cargo inside it.2PubMed. A cathepsin L-specific inhibitor preferentially inhibits degradation of autophagosomal LC3 and GABARAP in HeLa and Huh-7 cells That distinction matters because it means cathepsin L helps regulate how the autophagy machinery is recycled and reset, not just what gets digested.
Roles Beyond the Lysosome
Cathepsin L turns up in places you might not expect a digestive enzyme. In the immune system, it helps process a molecule called invariant chain, a chaperone that must be clipped away before immune cells can load fragments of foreign proteins onto their surfaces and present them to other immune cells. This step is essential for mounting a proper immune response, and cathepsin L shares the job with a related enzyme, cathepsin S.3PubMed. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation
In skin and hair, cathepsin L is required for normal development and cycling of hair follicles. Mice that lack the enzyme develop a striking phenotype: their hair follicles malfunction, the cells lining the hair canal fail to differentiate properly, and hair shafts cannot grow out normally.4PubMed Central. Cathepsin L Is Essential for Normal Epidermal Differentiation, Hair Follicle Morphogenesis, and Hair Cycling The underlying problem is hyperproliferation of keratinocytes, the skin cells that form the follicle lining, which disrupts the entire hair growth cycle.5PubMed. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling Cathepsin L was the first lysosomal protease shown to be essential for keeping the skin’s outer layer in balance, which hints that its reach extends well beyond simple protein cleanup.
Perhaps most surprising is cathepsin L’s moonlighting job inside the nucleus. During stem cell differentiation, the enzyme moves into the nucleus and clips the tail of histone H3, one of the proteins that DNA wraps around to stay organized.6PubMed Central. Cathepsin L Proteolytically Processes Histone H3 During Mouse Embryonic Stem Cell Differentiation Structural studies have confirmed exactly where cathepsin L grabs onto the histone tail and where the cut occurs.7PubMed Central. Structural basis for the recognition and cleavage of histone H3 by cathepsin L By trimming histones, cathepsin L appears to help remodel the landscape of gene expression as cells mature from a stem-like state into specialized types. This nuclear role will come up again in the context of cancer, where cathepsin L’s ability to shuttle between the cytoplasm and nucleus has consequences for drug resistance.
Cathepsin L and Heart Health
Heart muscle cells rely on cathepsin L to keep themselves clean. When the heart is under pressure, whether from high blood pressure or other stressors, cells need to ramp up protein turnover to prevent damaged proteins from piling up. In mice engineered to lack cathepsin L, the response to cardiac stress was significantly worse: lysosomal activity dropped, protein aggregates accumulated in heart muscle fibers, and the cells became less viable.8PubMed Central. Cathepsin-L ameliorates cardiac hypertrophy through activation of the autophagy-lysosomal dependent protein processing pathways In short, cathepsin L acts as a brake on pathological heart enlargement by keeping the protein-disposal system running.
On the vascular side, cathepsin L contributes to the remodeling of blood vessel walls. Smooth muscle cells in arteries use it to break down elastin and collagen, the structural fibers that give vessel walls their strength and flexibility. Under normal conditions this remodeling is tightly controlled, but in disease states like atherosclerosis, cathepsin L production ramps up. Patients with coronary artery narrowing had about two and a half times the serum cathepsin L levels of patients without detectable blockages, and the degree of artery narrowing correlated strongly with how much cathepsin L was circulating.9PubMed. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells Inflammatory signals from macrophages, smooth muscle cells, and the cells lining blood vessels all boost cathepsin L production, creating a feedback loop that weakens vessel walls. In mice lacking both cathepsin L and the receptor for LDL cholesterol, a high-fat diet produced less plaque than in mice missing only the LDL receptor, confirming that cathepsin L actively drives the breakdown of arterial structure during atherosclerosis.10PubMed. Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice
How Tumors Hijack Cathepsin L
Cancer cells exploit cathepsin L in several ways, and high levels of the enzyme are consistently linked to worse outcomes for patients. The overarching theme is that cathepsin L helps tumors break free from their original site, invade surrounding tissue, and establish themselves elsewhere. Its upregulation is common across many cancer types and correlates with metastatic aggressiveness.11PubMed Central. Cathepsin L targeting in cancer treatment
The most direct mechanism involves cathepsin L chewing through the extracellular matrix, the scaffolding of proteins that normally keeps tissues organized. When tumor cells overproduce cathepsin L, this scaffolding degrades, and the cells physically push into spaces they would not normally reach. This has been demonstrated in melanoma, where cathepsin L boosted both invasion and migration of tumor cells.12PubMed Central. Cathepsin L increases invasion and migration of B16 melanoma In ovarian cancer, cathepsin L has emerged as a key driver of this invasive behavior and is being studied as both a prognostic marker and a treatment target.13PubMed Central. Cathepsin L as a Driver of Tumour Invasion and a Novel Therapeutic Target in Ovarian Cancer
Beyond physical invasion, cathepsin L promotes a process called epithelial-mesenchymal transition (EMT), in which stationary epithelial cells take on the properties of mobile, invasive mesenchymal cells. Think of it as tumor cells reprogramming themselves for travel. In gastric cancer, macrophage-derived cathepsin L drove this transition while simultaneously shifting macrophages toward a tumor-friendly state, creating a cooperative environment that fueled metastasis.14PubMed Central. Macrophage-derived cathepsin L promotes epithelial-mesenchymal transition and M2 polarization in gastric cancer In lung cancer cell lines, silencing cathepsin L reversed EMT, while forcing cells to overexpress it triggered the transition.15PubMed Central. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells
Feeding the Tumor’s Blood Supply and Resisting Drugs
Tumors need blood vessels to grow, and cathepsin L helps them get them. When cathepsin L was knocked down or chemically blocked in breast cancer models, tumor-driven blood vessel formation dropped significantly. The inhibitor KGP94 reduced endothelial cell sprouting, migration, and tube formation in lab assays, and cathepsin L turned out to upregulate members of the cyclin family of proteins that push cells through division.16PubMed Central. Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94 In gastric cancer, cathepsin L drove angiogenesis through a different route, processing a transcription factor that then switched on production of a growth signal called VEGF-D.17PubMed Central. Cathepsin L promotes angiogenesis by regulating the CDP/Cux/VEGF-D pathway in human gastric cancer
Drug resistance is another area where cathepsin L causes trouble. Remember its nuclear histone-clipping activity? When cathepsin L enters the nucleus in cancer cells, it does more than trim histones. It degrades several proteins that chemotherapy drugs rely on to work, including estrogen receptor-alpha, topoisomerase-IIα, and histone deacetylase 1. When researchers added a cathepsin L inhibitor alongside the chemotherapy drug doxorubicin, not only was existing resistance reversed, but cancer cells were prevented from developing resistance in the first place. The combination also strongly suppressed drug-resistant tumors in mice.18PubMed Central. Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism
Cathepsin L as a Prognostic Marker
Given everything cathepsin L does for tumors, it is not surprising that measuring its levels in tumor tissue can predict outcomes. In hepatocellular carcinoma, patients whose tumors had low cathepsin L expression survived at about twice the rate over five years compared with those whose tumors had high levels.19PLoS ONE. Increased Expression of Cathepsin L: A Novel Independent Prognostic Marker of Worse Outcome in Hepatocellular Carcinoma Patients Similarly, in lung adenocarcinoma, high cathepsin L expression was associated with worse overall survival, and knocking it out in cell lines slowed tumor growth.20PubMed Central. Cathepsin L in Lung Adenocarcinoma: Prognostic Significance and Immunotherapy Response Through a Multi Omics Perspective These findings position cathepsin L not just as a therapeutic target but as a potential biomarker that could help clinicians tailor how aggressively they treat a given tumor.
The Virus Doorman
For certain viruses, cathepsin L is essentially the key that unlocks the door into a human cell. Viruses that enter cells through endosomes, the membrane-bound compartments that form when a cell swallows material from outside, encounter cathepsin L in those acidic compartments. The enzyme clips the virus’s surface proteins into a shape that can fuse with the cell membrane, completing entry.
This was first established for the original SARS coronavirus. Researchers showed that specific cathepsin L inhibitors blocked SARS-CoV from infecting cells, and demonstrated in a cell-free system that receptor binding followed by cathepsin L cleavage was sufficient to trigger membrane fusion.21PubMed Central. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry For Ebola virus, cathepsin L (sometimes working alongside cathepsin B) strips away a bulky glycan cap and a mucin-like domain from the viral glycoprotein, exposing the receptor-binding region hidden underneath. Structural studies confirmed that the cleaved intermediate binds tightly to a neutralizing antibody and can itself trigger the production of neutralizing antibodies, reinforcing the idea that this cleaved form is an obligatory step on the way to infection.22PubMed Central. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity
When SARS-CoV-2 emerged, cathepsin L’s role was again front and center. The virus can enter cells via two routes: one using a surface protease called TMPRSS2 and another using cathepsin L inside endosomes. Researchers discovered two previously unknown cathepsin L cleavage sites on the SARS-CoV-2 spike protein, both highly conserved across all known variants including Omicron. Structural work showed that cathepsin L cleavage pushed the spike into an activated “up” conformation that favored receptor binding and membrane fusion.23Cell Discovery. Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies Which pathway a given SARS-CoV-2 variant prefers can depend on single amino acid changes in the spike protein. The H655Y mutation, for example, skewed tropism toward cell types that depend on cathepsin L for entry rather than TMPRSS2.24PLoS One. Amino acid residues 655 and 969 in the spike protein of Omicron subvariant BA.1 control use of TMPRSS2 versus Cathepsin L dependent entry pathways and cell tropism
Because these two entry pathways can compensate for each other, computational modeling has suggested that blocking both TMPRSS2 and cathepsin L simultaneously could be synergistic, not just additive, against SARS-CoV-2 infection.25PLoS Computational Biology. Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection This idea has shaped antiviral strategy discussions, since targeting only one pathway leaves the virus a backup route.
Developing Cathepsin L Inhibitors
The list of diseases in which cathepsin L plays a damaging role naturally raises the question: can we just block it? Researchers have been working on this from multiple angles. Small molecule inhibitors are the most advanced approach. A library of compounds built around fused ring structures yielded several that inhibit cathepsin L at sub-micromolar concentrations, with the best achieving strong selectivity over the closely related cathepsin B.26PubMed. Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks On the antiviral side, crystal structures of cathepsin L bound to 14 different inhibitor compounds at high resolution are providing a detailed blueprint for designing better drugs. Several of these compounds, originally developed as broad cysteine protease inhibitors, showed antiviral activity against SARS-CoV-2 at very low nanomolar concentrations in cell assays.27PubMed Central. Structural Elucidation and Antiviral Activity of Covalent Cathepsin L Inhibitors
One challenge is specificity. The cathepsin family has many members with overlapping functions, and blocking the wrong one, or all of them at once, could disrupt normal physiology. The body also has its own cathepsin L inhibitors. Cystatin F, for instance, naturally regulates cathepsin L activity in immune cells as they mature, and both intact and truncated forms of this protein are potent inhibitors.28PubMed. Regulation of cathepsins S and L by cystatin F during maturation of dendritic cells Understanding how the body’s own regulatory systems work is informing drug design: the goal is to dial cathepsin L down in the right tissues at the right time, not shut it off everywhere.
A newer approach involves conjugating cathepsin inhibitors to antibodies that recognize markers on specific cell types. By attaching inhibitors to antibodies that home in on cancer cell surface proteins, researchers aim to deliver the drug precisely where it is needed, potentially avoiding the side effects of systemic inhibition.29PubMed Central. A Review of Small Molecule Inhibitors and Functional Probes of Human Cathepsin L
Cathepsin L in Neurodegeneration
The brain presents a particularly interesting case because cathepsin L’s dual nature is on full display. Neurons depend heavily on lysosomal function to clear the misfolded protein aggregates that accumulate in Alzheimer’s, Parkinson’s, and Huntington’s diseases. When cathepsin activity is insufficient, toxic proteins build up and damage neurons. But excessive or mislocalized cathepsin activity can also harm cells.30PubMed Central. Targeting Cathepsins in Neurodegeneration: Biochemical Advances
Researchers are exploring whether adding cathepsin L back into the system could help. In models of neuronal ceroid lipofuscinosis, a group of inherited neurodegenerative diseases marked by lysosomal storage problems, treating brain tissue with recombinant pro-cathepsin L reduced levels of a toxic storage protein called saposin-C and lessened reactive scarring by support cells in the brain. Cathepsin B did not achieve the same effect, though both enzymes were efficiently taken up into neuronal lysosomes when injected into the brain.31PubMed. Analysis of cathepsin B and cathepsin L treatment to clear toxic lysosomal protein aggregates in neuronal ceroid lipofuscinosis More recently, in cell and mouse models of Parkinson’s disease-related alpha-synuclein pathology, treatment with recombinant cathepsin L reduced multiple forms of pathological alpha-synuclein and improved lysosomal function, measured by the recovery of another lysosomal enzyme’s activity.32PubMed Central. Recombinant cathepsins B and L promote α-synuclein clearance and restore lysosomal function in human and murine models with α-synuclein pathology
These findings are early-stage and come with caveats. The neuronal ceroid lipofuscinosis study found that cathepsin L treatment did not improve weight loss or mortality in the mouse model, and the broader picture suggests that effective protein clearance in the brain requires a hierarchical process involving multiple types of lysosomal enzymes, not just one. Still, the ability to deliver active protease to neuronal lysosomes and measurably reduce toxic protein is a proof of concept worth watching.
An Ancient and Expanding Gene Family
Cathepsin L is not a recent evolutionary invention. Comparative genomic studies across 22 vertebrate species, from sea squirts to humans, found that every species examined carried at least one copy of cathepsin L or a closely related gene. The family has expanded over evolutionary time through gene duplication events, with some lineage-specific expansions: zebrafish duplicated cathepsin L itself, frogs expanded cathepsins S and K, and rodents underwent extensive tandem duplication of cathepsin L1 genes. In placental mammals, a close relative called cathepsin V (also known as cathepsin L2) appeared and always sits near cathepsin L1 on the same chromosome, suggesting it arose from a duplication and then took on distinct functions.33PubMed Central. Evolutionary History of Cathepsin L (L-like) Family Genes in Vertebrates The fact that cathepsin L has been retained and expanded across such a wide range of species underscores just how fundamental its functions are, and why completely eliminating its activity would carry steep biological costs. That deep conservation is worth keeping in mind as researchers work toward therapies that modulate rather than erase it.